LMNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LMNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Luminex's average Accounts Receivable for the three months ended in Mar. 2021 was $68.0 Mil. Luminex's Revenue for the three months ended in Mar. 2021 was $110.7 Mil. Hence, Luminex's Days Sales Outstanding for the three months ended in Mar. 2021 was 56.06.
The historical rank and industry rank for Luminex's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Luminex's highest Days Sales Outstanding was 58.88. The lowest was 40.67. And the median was 48.23.
Luminex's Days Sales Outstanding declined from Mar. 2020 (60.40) to Mar. 2021 (56.06).
The historical data trend for Luminex's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luminex Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 41.28 | 43.46 | 54.34 | 59.56 | 53.68 |
Luminex Quarterly Data | ||||||||||||||||||||
Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 60.40 | 51.89 | 52.11 | 52.19 | 56.06 |
For the Medical Instruments & Supplies subindustry, Luminex's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Luminex's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Luminex's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Luminex's Days Sales Outstanding for the fiscal year that ended in Dec. 2020 is calculated as
Days Sales Outstanding (A: Dec. 2020 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2019 ) | + | Accounts Receivable (A: Dec. 2020 )) | / | count ) | / | Revenue (A: Dec. 2020 ) | * | Days in Period |
= | ( (55.815 | + | 66.963) | / | 2 ) | / | 417.396 | * | 365 |
= | 61.389 | / | 417.396 | * | 365 | ||||
= | 53.68 |
Luminex's Days Sales Outstanding for the quarter that ended in Mar. 2021 is calculated as:
Days Sales Outstanding (Q: Mar. 2021 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2020 ) | + | Accounts Receivable (A: Mar. 2021 )) | / | count ) | / | Revenue (A: Mar. 2021 ) | * | Days in Period |
= | ( (66.963 | + | 69.051) | / | 2 ) | / | 110.688 | * | 365 / 4 |
= | 68.007 | / | 110.688 | * | 365 / 4 | ||||
= | 56.06 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luminex (NAS:LMNX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Luminex's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Harriss T Currie | officer: SVP, Finance & CFO | 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727 |
Todd C. Bennett | officer: SVP, Global Sales & Cust Ops | 12212 TECHNOLOGY BLVD. AUSTIN TX 78727 |
Stephen L. Eck | director | 12212 TECHNOLOGY BLVD., AUSTIN TX 78727 |
Edward A Ogunro | director | |
Eric Shapiro | officer: SR VP, GLOBAL MARKETING | 12212 TECHNOLOGY BLVD. AUSTIN TX 78727 |
Nachum Shamir | director, officer: President & CEO | 12212 TECHNOLOGY BLVD, AUSTIN TX 78727 |
Rew Richard W. Ii | officer: SVP, Gen Counsel & Corp Secy | 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735 |
Nancy Fairchild | officer: SVP, Human Resources | 12212 TECHNOLOGY BLVD. AUSTIN TX 78727 |
G Walter Lowenbaum | director | C/O 3D SYSTEMS CORPORATION, 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730 |
Randall Myers | officer: SVP, Global Mfg and Quality | 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727 |
Charles J. Collins | officer: SR VP, R&D - US | 12212 TECHNOLOGY BLVD. AUSTIN TX 78727 |
Dijuana K Lewis | director | 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Jim D Kever | director | C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355 |
Thomas W Erickson | director | OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108 |
Kenneth A Samet | director | 800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850 |
From GuruFocus
By PRNewswire PRNewswire • 05-20-2021
By PRNewswire PRNewswire • 04-26-2021
By GF Value GF Value • 03-31-2021
By PRNewswire PRNewswire • 04-17-2021
By PRNewswire PRNewswire • 05-24-2021
By [email protected] insider • 07-30-2020
By PRNewswire PRNewswire • 12-16-2020
By PRNewswire PRNewswire • 07-12-2021
By PRNewswire PRNewswire • 09-25-2020
By PRNewswire PRNewswire • 04-26-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.